IKT — Inhibikase Therapeutics Income Statement
0.000.00%
- $10.82m
- $1.07m
- $0.26m
Annual income statement for Inhibikase Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.12 | 0.698 | 3.1 | 0.123 | 0.261 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 6.82 | 3.52 | 17.9 | 18.3 | 20.4 |
Operating Profit | -5.7 | -2.82 | -14.8 | -18.1 | -20.1 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -5.72 | -2.85 | -14.8 | -18.1 | -19 |
Net Income After Taxes | -5.72 | -2.85 | -14.8 | -18.1 | -19 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.72 | -2.85 | -14.8 | -18.1 | -19 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.72 | -2.85 | -14.8 | -18.1 | -19 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.67 | -2.08 | -3.53 | -4.3 | -3.57 |
Dividends per Share |